Message From the Editor-in-Chief

Toyoaki Murohara, MD, PhD

Dear Colleagues,

On behalf of the *Circulation Journal*, I would like to report the official 2017 impact factor and the *Circulation Journal* papers (2015–2016) most frequently quoted in 2017, that substantially contributed to the 2017 impact factor of the Journal.

1. The Official 2017 Impact Factor

I would like to report that *Circulation Journal* has earned an official 2017 Impact Factor (IF) of **2.895**. The score decreased from the previous year (3.544). The official ranking places *Circulation Journal* the **54th** among the **128** journals in the Cardiac & Cardiovascular Systems category in 2017 JCR Science Edition (44th among the 126 journals in 2016). Although the IF score decreased from the previous year, the IF score without self-citation increased from 2.449 to 2.624. I would like to ask readers to use *Circulation Journal* papers as reference papers in your future submission of manuscripts to any journals.

2. The Most Frequently Quoted CJ Papers (2015–2016) in 2017

The following papers, published in 2015–2016, were among the top **23** most frequently quoted papers in 2017, thereby substantially contributing to the 2017 Impact Factor of the Journal (number in the parenthesis denoted the number of quotation in 2015–2016).

1. (22) Harada M, Van Wagoner DR, Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management. *Circ J* 2015; **79**: 495–502.
2. (18) Suzuki S, Yamashita T, Okumura K, Atarashi H, Akao M, Ogawa H, et al. Incidence of ischemic stroke in Japanese patients with atrial fibrillation not receiving anticoagulation therapy: Pooled analysis of the Shinken Database, J-RHYTHM Registry, and Fushimi AF Registry. *Circ J* 2015; **79**: 432–438.
3. (15) Goto S, Huang CH, Park SJ, Emanuelsson H, Kimura T. Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome: Randomized, double-blind, phase III PHILO study. *Circ J* 2015; **79**: 2452–2460.
- (15) Tada H, Kawashiri M, Yoshida T, Teramoto R, Nohara A, Konno T, et al. Lipoprotein(a) in familial hypercholesterolemia with proprotein convertase subtilisin/kexin type 9 (*PCSK9*) gain-of-function mutations. *Circ J* 2016; **80**: 512–518.
- (15) Teramoto T, Kobayashi M, Tasaki H, Yagyu H, Higashikata T, Takagi Y, et al. Efficacy and safety of alirocumab in Japanese patients with heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with statins: ODYSSEY JAPAN Randomized Controlled Trial. *Circ J* 2016; **80**: 1980–1987.
6. (14) Kario K, Ogawa H, Okumura K, Okura T, Saito S, Ueno T, et al; on behalf of the SYMPLICITY HTN-Japan Investigators. SYMPLICITY HTN-Japan: First randomized controlled trial of catheter-based renal denervation in Asian patients. *Circ J* 2015; **79**: 1222–1229.
7. (12) Dvir D, Webb JG. Transcatheter aortic valve-in-valve implantation for patients with degenerative surgical bioprosthetic valves. *Circ J* 2015; **79**: 695–703.
8. (11) Ushigome R, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, et al; on behalf of the CHART-2 Investigators. Temporal trends in clinical characteristics, management and prognosis of patients with symptomatic heart failure in Japan: Report from the CHART studies. *Circ J* 2015; **79**: 2396–2407.

Released online July 13, 2018

Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan

Mailing address: Toyoaki Murohara, MD, PhD, Department of Cardiology, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa-ku, Nagoya 466-8550, Japan. E-mail: murohara@med.nagoya-u.ac.jp

ISSN-1346-9843 All rights are reserved to the Japanese Circulation Society. For permissions, please e-mail: cj@j-circ.or.jp

- (11) Niki T, Wakatsuki T, Yamaguchi K, Taketani Y, Oeduka H, Kusunose K, et al. Effects of the addition of eicosapentaenoic acid to strong statin therapy on inflammatory cytokines and coronary plaque components assessed by integrated backscatter intravascular ultrasound. *Circ J* 2016; **80**: 450–460.
- (11) Greenberg B. Novel therapies for heart failure: Where do they stand? *Circ J* 2016; **80**: 1882–1891.
11. (10) Bulluck H, Maestrini V, Rosmini S, Abdel-Gadir A, Treibel TA, Castelletti S, et al. Myocardial T1 mapping: Hope or hype? *Circ J* 2015; **79**: 487–494.
- (10) Calkins H. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: Three decades of progress. *Circ J* 2015; **79**: 901–913.
- (10) Hibi K, Kimura K, Umemura S. Clinical utility and significance of intravascular ultrasound and optical coherence tomography in guiding percutaneous coronary interventions. *Circ J* 2015; **79**: 24–33.
- (10) Maeda K, Kuratani T, Torikai K, Mizote I, Ichibori Y, Onishi T, et al. New self-expanding transcatheter aortic valve device for transfemoral implantation: Early results of the first-in-Asia implantation of the ACURATE Neo/TF™ system. *Circ J* 2015; **79**: 1037–1043.
- (10) Shiomi H, Morimoto T, Furukawa Y, Nakagawa Y, Sakata R, Okabayashi H, et al; on behalf of the CREDO-Kyoto PCI/CABG registry cohort-2 investigators. Comparison of percutaneous coronary intervention with coronary artery bypass grafting in unprotected left main coronary artery disease: 5-year outcome from CREDO-Kyoto PCI/CABG Registry Cohort-2. *Circ J* 2015; **79**: 1282–1289.
- (10) Shiraishi S, Sakamoto F, Tsuda N, Yoshida M, Tomiguchi S, Utsunomiya D, et al. Prediction of left main or 3-vessel disease using myocardial perfusion reserve on dynamic thallium-201 single-photon emission computed tomography with a semiconductor gamma camera. *Circ J* 2015; **79**: 623–631.
17. (9) Enomoto M, Ishizu T, Seo Y, Yamamoto M, Suzuki H, Shimano H, et al. Subendocardial systolic dysfunction in asymptomatic normotensive diabetic patients. *Circ J* 2015; **79**: 1749–1755.
- (9) Koyama J, Ikeda S, Ikeda U. Echocardiographic assessment of the cardiac amyloidoses. *Circ J* 2015; **79**: 721–734.
- (9) Craige SM, Kant S, Keaney JF Jr. Reactive oxygen species in endothelial function: From disease to adaptation. *Circ J* 2015; **79**: 1145–1155.
- (9) Nakamura M, Nishikawa M, Komuro I, Kitajima I, Uetsuka Y, Yamagami T, et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). *Circ J* 2015; **79**: 1230–1236.
- (9) de Zeeuw P, Wong BW, Carmeliet P. Metabolic adaptations in diabetic endothelial cells. *Circ J* 2015; **79**: 934–941.
- (9) Oba T, Yasukawa H, Nagata T, Kyogoku S, Minami T, Nishihara M, et al. Renal nerve-mediated erythropoietin release confers cardioprotection during remote ischemic preconditioning. *Circ J* 2015; **79**: 1557–1567.
- (9) Sotomi Y, Onuma Y, Dijkstra J, Eggermont J, Liu S, Tenekecioglu E, et al. Impact of implantation technique and plaque morphology on strut embedment and scaffold expansion of polylactide bioresorbable scaffold: Insights from ABSORB Japan Trial. *Circ J* 2016; **80**: 2317–2326.

The Editorial Team looks forward to receiving manuscripts with high scientific impact from all over the world.

Toyoaki Murohara, MD, PhD

Editor-in-Chief
Circulation Journal